Novartis cannot block drugmaker MSN Pharmaceuticals from launching a generic version of its blockbuster heart-failure drug ...

Strong sales of Entresto, Kisqali, Kesimpta, Leqvio and Scemblix have likely benefited NVS' Q2 performance and offset the ...

Divi's Labs makes active pharmaceutical ingredients for Entresto for Novartis, which contributes nearly 8% to Hyderabad-based ...

The company's quarterly core operating profit--the company's preferred earnings metric, which strips out exceptional and other one-off items--is forecast at $5.75 billion, according to the same ...

The shares of one of India's leading API manufacturers, engaged in the production and export of APIs, intermediates, and ...

A Delaware federal judge has ruled that Novartis cannot prevent MSN Pharmaceuticals from introducing a generic version of its ...

Brokerage firm IIFL has warned that due to this development, Divi's Laboratories' annual Earnings Before Interest, Tax, ...

A U.S. judge ruled against Novartis, allowing MSN Pharmaceuticals to launch a generic version of Entresto prior to its patent expiry next year. Novartis plans to appeal the decision, which could ...

Bayer announced the FDA approved finerenone, a nonsteroidal selective mineralocorticoid receptor antagonist, for the ...

Medicare Part D usually covers Entresto. However, the exact cost of Entresto can vary. In 2022, according to the most recent data, the annual out-of-pocket cost for Entresto for people with ...